NADPH-dependent diflavin oxidoreductase 1 (novel reductase 1, NADPH-dependent FMN & FAD containing oxidoreductase, NDOR1, NR1)

Function

• oxidoreductase that catalyzes the NADP-dependent reduction of cytochrome c & one-electron acceptors, such as doxorubicin, K+ ferricyanide & menadione (in vitro)
• interacts with DCPS

Cofactor: FMN, FAD

Kinetic parameters:

• KM=21 uM for cytochrome c
• Vmax=1.2 umol/min/ug enzyme for cytochrome c reduction
• Optimum pH is about 8.0

Structure

• in the C-terminal section, belongs to the flavoprotein pyridine nucleotide cytochrome reductase family
• contains 1 FAD-binding domain
• contains 1 flavodoxin-like domain

Compartment

cytoplasm, concentrated in perinuclear structure

Alternative splicing

named isoforms=2

Expression

• low expression in brain, heart, kidney, pancreas, prostate & skeletal muscle
• highest levels in the placenta

Pathology

• expressed in cancer cell lines including promyelocytic leukemia, HeLa S3, chronic myelogenous leukemia, lymphoblastic leukemia, Burkitt's lymphoma, colorectal adenocarcinoma, lung carcinoma, & melanoma G361
• overexpression enhances cytotoxicity of menadione, & consequently induced cell death; coexpression with DCPS diminished this toxicity

More general terms

• oxidoreductase

Database

• Kegg: http://www.genome.jp/dbget-bin/www_bget?hsa:2715
• OMIM: https://mirror.omim.org/entry/606073
• UniProt: http://www.uniprot.org/uniprot/Q9UHB4.html